FREDERICK, Md., May 16 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today that the company filed a 510(k) Market Clearance application for its new ActiPulse(TM) device with the Food and Drug Administration. ActiPulse(TM) requested indication for use is “the adjunctive use in the palliative treatment of post operative pain and edema in superficial soft tissue.”
Andrew J. Whelan, President, stated, “This new device will broaden our sales and market scope into palliative treatment of postoperative edema and pain in superficial soft tissues.”
BioElectronics currently manufactures and sells ActiPatch(TM), a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost- effective, patient friendly method to reduce soft tissue pain and swelling.
This device is currently investigational and not cleared for sale by the FDA, nor is it currently available for purchase in the United States.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics Corporation
CONTACT: Andrew J. Whelan, President & CEO, or Thomas O’Connor, EVPOperations & COO, both of BioElectronics Corporation, +1-301-644-3906, Fax:+1-301-644-3939, info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com/
